Broad Intellectual Property
For well over a decade, Genus Oncology has aggressively pursued intellectual property protection relating to various aspects of MUC1’s biologic activity. In conjunction with our academic partner – The Dana-Farber Cancer Institute – we have filed numerous patents in the U.S. and around the world that target key scientific and developmental programs. At present, our portfolio consists of 10 issued U.S. Patents, and 29 issued foreign patents, all of which are either owned or co-owned by Genus Oncology. We believe that the additional pending applications we own or co-own (3 U.S.; 9 foreign) will further bolster our portfolio once issued.
Our intellectual property falls into three general areas:
In addition to this strong IP portfolio, our lead drug GO-203 is further supported by US FDA Orphan Drug Designation for Relapsed/Refractory Acute Myeloid Leukemia, which provides extended market protection.
Our intellectual property falls into three general areas:
- Our therapeutic peptide program is supported by three different patent families, each with issued patents. Complementary filings where our therapeutic peptide therapy is combined with other treatment regimens also enhance the value of this technology.
- We have made patent filings relating to a number of different MUC1-binding antibodies (to both extracellular and cytoplasmic domains) for diagnostic and/or therapeutic uses.
- We have a number of supporting patents that cover drug screening and the exploitation of agents that impair MUC1-C’s ability to interact with various cellular proteins that contribute to MUC-1 oncogenic actions.
In addition to this strong IP portfolio, our lead drug GO-203 is further supported by US FDA Orphan Drug Designation for Relapsed/Refractory Acute Myeloid Leukemia, which provides extended market protection.
